Research programme: immunological disorders therapeutics - Undisclosed company

Drug Profile

Research programme: immunological disorders therapeutics - Undisclosed company

Latest Information Update: 16 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Class Immunotherapies; Peptides
  • Mechanism of Action Immunosuppressants; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Autoimmune disorders; Hypersensitivity

Most Recent Events

  • 25 Apr 2017 Early research in Hypersensitivity and Autoimmune disorders (Parenteral)
  • 25 Apr 2017 An unknown global pharmaceutical company in-licenses Tregitope Technology from EpiVax
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top